On September 3, 2025 First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, reported a new collaboration with the Fight Colorectal Cancer Foundation (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment (Press release, First Ascent Biomedical, SEP 3, 2025, https://firstascentbiomedical.com/first-ascent-biomedical-and-fight-colorectal-cancer-foundation-announce-groundbreaking-study-to-advance-precision-oncology-for-colorectal-cancer-patients/?utm_source=rss&utm_medium=rss&utm_campaign=first-ascent-biomedical-and-fight-colorectal-cancer-foundation-announce-groundbreaking-study-to-advance-precision-oncology-for-colorectal-cancer-patients [SID1234655876]). Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent’s cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Fight CRC is committed to empowering patients through innovation," said Davis. "This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options."

The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent’s xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes.

Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent’s Chief Technology Officer and the study’s principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient’s unique cancer.

"This collaboration with the Fight Colorectal Cancer Foundation is another important step in transforming how we approach cancer treatment," said Jim Foote, founder and chief executive officer, First Ascent Biomedical. "We are honored to be part of this effort."

The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on ClinicalTrials.gov.

On September 3, 2025 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada (Press release, C4 Therapeutics, SEP 3, 2025, View Source [SID1234655721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMS Annual Meeting 2025 Oral Presentation
Title: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Presentation Date and Time: Saturday, September 20, 2025 at 11:10 am ET
Session: Future Targets and New Modalities of Therapy
Location: Metro Toronto Convention Centre – South Building, Room 701
Presenter: Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology

C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The presentation at the IMS Annual Meeting will include data from all safety and efficacy evaluable MM patients from all dose levels studied in the cemsidomide with dexamethasone cohort in the Phase 1 trial. C4T’s investor webcast will highlight the data from the oral presentation at the IMS Annual Meeting and provide additional detail on the company’s planned next steps of clinical development.

C4T Investor Webcast
C4T will host a webcast on September 20, 2025 at 3 pm ET. To join the webcast, please visit this link or the "Events & Presentations" page of the Investors section on the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived and available following the event. Additionally, following the oral presentation at the IMS Annual Meeting, C4T will share that presentation on its website under the Scientific Presentations and Publications page.

On September 3, 2025 Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, reported the closing of a $59 million series B financing (Press release, Mercy BioAnalytics, SEP 3, 2025, View Source [SID1234655738]). The round was co-led by Novalis and Sozo Ventures, with participation from Perceptive Xontogeny Venture Fund, American Cancer Society BrightEdge and iSelect Fund, as well as funds committed to women’s health and leadership including Portfolia, Avestria Ventures, and Mindshift Capital. The round also included significant participation from strategic investors including Hologic, Bruker Scientific, and Labcorp.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Coincident with the financing, Mercy is pleased to welcome Rob Freelen to the Board of Directors. A Managing Director and investment partner at Sozo Ventures, Mr. Freelen brings a wealth of experience as a seasoned Director, successful entrepreneur and former executive at Silicon Valley Bank. "Sozo is proud to co-lead this round and help usher in a new generation of cancer diagnostics with the potential to save lives at scale."

The financing will support the commercialization of Mercy’s blood-based ovarian cancer test portfolio, designed to detect ovarian cancer at earlier, more treatable stages across multiple indications. The Mercy Halo ovarian cancer screening test exhibits unprecedented sensitivity and specificity for the detection of pre-clinical high grade serous ovarian carcinoma in post-menopausal women based on a blinded evaluation of samples from a randomized controlled trial.

The funds will additionally enable the expansion of the Mercy Halo portfolio, including multi-cancer and lung cancer screening tests.

"This financing accelerates our efforts to bring transformative early cancer detection tests to patients and providers," said Dawn Mattoon, Ph.D., Chief Executive Officer of Mercy. "We are grateful for the support of our investors and proud to partner with those who share our mission to save lives and relieve suffering through the early detection of cancer."

"We believe Mercy is building one of the most promising early detection platforms in oncology," said Paul Meister, Partner at Novalis. "Their technology addresses a critical gap in current cancer screening, and we’re excited to support the team as they continue to deliver on critical regulatory, clinical, and commercial milestones."

On September 3, 2025 First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, reported a new collaboration with the Fight Colorectal Cancer Foundation (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment (Press release, First Ascent Biomedical, SEP 3, 2025, https://firstascentbiomedical.com/first-ascent-biomedical-and-fight-colorectal-cancer-foundation-announce-groundbreaking-study-to-advance-precision-oncology-for-colorectal-cancer-patients/?utm_source=rss&utm_medium=rss&utm_campaign=first-ascent-biomedical-and-fight-colorectal-cancer-foundation-announce-groundbreaking-study-to-advance-precision-oncology-for-colorectal-cancer-patients [SID1234655876]). Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent’s cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Fight CRC is committed to empowering patients through innovation," said Davis. "This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options."

The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent’s xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes.

Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent’s Chief Technology Officer and the study’s principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient’s unique cancer.

"This collaboration with the Fight Colorectal Cancer Foundation is another important step in transforming how we approach cancer treatment," said Jim Foote, founder and chief executive officer, First Ascent Biomedical. "We are honored to be part of this effort."

The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on ClinicalTrials.gov.

On September 3, 2025 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, reported the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts (Press release, Cellectar Biosciences, SEP 3, 2025, View Source [SID1234655725]). The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present our poster at the AACR (Free AACR Whitepaper) Special Conference on Pancreatic Cancer, further showcasing the potential of CLR 121225 for solid tumors," said Jarrod Longcor, chief operating officer of Cellectar. "We are encouraged that preclinical studies to date have demonstrated excellent activity, biodistribution and uptake of CLR 225 across multiple solid tumor animal models and are currently advancing IND-enabling activities."

Details of the poster presentation are as follows:

Title: "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate"
Poster: B032
Date/Time: Tuesday, September 30, 6-9 p.m. Presenter: Jarrod Longcor